Chemical Information | |
Antiviral agent ID | DrugRepV_1284 | |
Antiviral agent name | Perphenazine | |
IUPAC Name | 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol | |
SMILES (canonical) | C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO | |
Molecular Formula | C21H26ClN3OS | |
Molecular Weight (g/mol) | 403.97 | |
InChl | InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2 | |
Common Name | Perphenazine | |
Synonyms | 2-(4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol | 2-chloro-10-(3-(4-(2-Hydroxyethyl)piperazin-1-yl)propyl)phenothiazine | 4-[3-(2-chloro-10H-Phenothiazin-10-yl)propyl]-1-piperazineethanol | 4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol | Chlorpiprazine | Etaperazin | Etaperazine | Ethaperazine | gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine | Perfenazina | Perfenazine | Perphenazin | Perphénazine | Perphenazinum | |
Structural Information | |
|
|
Clinical Information | |
Category | Nervous System
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Psychosis | Nausea and vomiting in adults
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 42.76 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |